ASBP

Aspire Biopharma Holdings, Inc. (ASBP) | Rumor.io

Aspire Biopharma Holdings

ASBP

Attention (50-day avg)0%

Attention rank (50-day avg)#3,474

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.02

Market capitalization11.9M

Earnings per share-6.65

Dividend yield (TTM)—

Revenue (annual)6.2K

Net income (annual)-24.5M

Social

What share of all stock conversation is about ASBP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0.01% +0

Sep 9

Aspire Biopharma Holdings, Inc. (ASBP) has approved a $10 million share repurchase program, which is approximately 80% of its current market capitalization.
The company's board of directors has authorized the share buyback, and it is expected to boost the stock price once trading volume increases.
Aspire-Lakewood Holdings' financial performance is strong, with its parent company, DCSC, reporting revenue of approximately $209.5 million and Adjusted EBITDA of $22.3 million in FY2025.

Generated by AI

Sentiment

Of the messages about ASBP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	87.45% -3.02
Bearish	—	—	0% 0	12.55% +3.02

Bullish· Jun 12

$ASBP broke the high of day and needs to break the new high of day at 10.29 to continue its uptrend.
Aspire Biopharma's acquisition of Dura Driver Control Systems is expected to bring in $200M+ in 2025 revenue, making it a solid investment opportunity.
$ASBP has a low float of 1.3M, which can lead to significant price increases, and its recent acquisition news has already led to a 16% price increase.

Bearish· Jun 12

The company has experienced significant dilution, which may be a concern for investors.
There are a large number of short sellers in the market, which could put downward pressure on the stock price.
The company's stock price has declined by 41,000 dollars for some investors, indicating a potential loss of value.

Generated by AI

Topics

Of the messages about ASBP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	85.71%	16.92%
Technical Analysis	—	—	0%	11.4%
Controversies	—	—	14.29%	0.21%
Analysts	—	—	0%	38.57%
Earnings	—	—	0%	0%
Macro	—	—	0%	32.91%

Announcements· Apr 27

Aspire Biopharma Holdings, Inc. (ASBP) announced a $5 million share buyback program, funded from existing cash.
The company recently raised $21 million in preferred stock offerings in February and April 2026, which was dilutive.
ASBP also announced the acquisition of Dura Control Systems, a global automotive supplier with $200 million in revenue for 2025.

Technical Analysis· Nov 18

$ASBP is showing signs of accumulation, with buyers defending the.10 level three times and every dip since the low being bought instantly.
The stock is displaying textbook strength, with volume exploding on green candles and dying on red, and still holding higher lows and coiling for a potential second leg.
A break over.115 could send the stock back to.12 →.135, with shorts potentially getting caught off guard.

Generated by AI

Community

Of the messages about ASBP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	33.33%	31.82%	28.27%
Newcomers	0%	66.67%	68.18%	71.73%

Regulars· Sep 9

The Aspire-Lakewood Holdings Board has approved a $10M share repurchase program, effective immediately, which is backed by the company's 2025 revenue of ~$209.5M and Adjusted EBITDA of $22.3M.
The company's financial performance has improved, with DCSC H1 2026 revenue of ~$103.9M and Adjusted EBITDA of $10.5M, indicating a growth trend.
The company's previous CEO's legal problems led to a contingent purchase-price obligation, which was satisfied through future sales of the product, and the intellectual property was successfully transferred to Aspire-Lakewood.

Newcomers· Aug 11

Aspire Biopharma's stock price has surged by 77.62% to $7.79, with strong breakout and pumping volume observed.
The company has announced a $30M deal to acquire DCS, expanding its business into the global automotive industry and diversifying its revenue streams into new markets.
Aspire Biopharma's stock has broken out and is pumping higher, with clear breakout signals and explosive surge observed, indicating a strong momentum in the market.

Generated by AI

Brings total authorized repurchase to $10 millionReflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunityIncreased authorization supported by strength of newly acquired Dura Control Systems Corp's (DCSC) full year 2025 and six months ended June 30, 2026 revenue of approximately $209.5 million and Adjusted EBITDA1 of $22.

21d agoYahoo Finance

Aspire Biopharma changes name to Aspire-Lakewood Holdings

21d agoInvesting.com

Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.

ESTERO, FL / ACCESS Newswire / September 8, 2026 / (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it has changed its corporate name from "" to "Aspire-Lakewood Holdings, Inc." The name change is effective upon the filing of a Certificate of Amendment to the Company's Certificate of Incorporation with the Secretary of State of the State of Delaware.

21d agoYahoo Finance

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at Sidoti & Company's Micro-Cap ...

1mo agoYahoo Finance

EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal

Aspire Biopharma Holdings Inc. said Monday it completed its $30 million acquisition of Dura Driver Control Systems, expanding the biopharmaceutical company into the automotive and mobility-control market. The deal, first announced in June, gives Aspire 100% ownership of Dura Driver...

1mo agoYahoo Finance

Also Discussed

Investors talking about ASBP also mention

#	Name	Attention
1	UTime LimitedWTO	0%0
2	VIVK - Vivakor, Inc.	——
3	IVP - Inspire Veterinary Partners, Inc.	——
4	OSR Health, Inc.OSRH	0.01%+0
5	UOKA - MDJM Ltd	——
6	Jet.AI Inc.JTAI	0%new
7	Paranovus Entertainment Technology Ltd.PAVS	0%new
8	Autozi Internet Technology (Global) Ltd. Class AAZI	0%new
9	SOND - Sonder Holdings Inc.	——
10	Intensity Therapeutics, Inc.INTS	0%0

Aspire Biopharma Holdings, Inc.

Consumer Cyclical
Auto Parts

Aspire Biopharma Holdings, Inc. is a biopharmaceutical company focused on developing and marketing sublingual delivery technologies for drugs, nutraceuticals, and supplements. Its platform is designed to improve how active ingredients are absorbed by bypassing the gastrointestinal tract, with applications centered on faster onset and more precise administration. The company’s current portfolio includes soluble and fast-acting formulations, such as aspirin-based products for cardiology emergencies and pain management, along with other development programs spanning wellness and specialty therapeutic categories. Aspire Biopharma Holdings, Inc. operates at the intersection of pharmaceuticals and drug-delivery innovation, serving markets that value rapid absorption, dosage control, and alternative delivery formats for established compounds.

Website

Location

23150 Fashion Drive

Estero, FL, 33928

United States

Social

What share of all stock conversation is about ASBP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0.01% +0

Sep 9

Aspire Biopharma Holdings, Inc. (ASBP) has approved a $10 million share repurchase program, which is approximately 80% of its current market capitalization.
The company's board of directors has authorized the share buyback, and it is expected to boost the stock price once trading volume increases.
Aspire-Lakewood Holdings' financial performance is strong, with its parent company, DCSC, reporting revenue of approximately $209.5 million and Adjusted EBITDA of $22.3 million in FY2025.

Generated by AI

Sentiment

Of the messages about ASBP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	87.45% -3.02
Bearish	—	—	0% 0	12.55% +3.02

Bullish· Jun 12

$ASBP broke the high of day and needs to break the new high of day at 10.29 to continue its uptrend.
Aspire Biopharma's acquisition of Dura Driver Control Systems is expected to bring in $200M+ in 2025 revenue, making it a solid investment opportunity.
$ASBP has a low float of 1.3M, which can lead to significant price increases, and its recent acquisition news has already led to a 16% price increase.

Bearish· Jun 12

The company has experienced significant dilution, which may be a concern for investors.
There are a large number of short sellers in the market, which could put downward pressure on the stock price.
The company's stock price has declined by 41,000 dollars for some investors, indicating a potential loss of value.

Generated by AI

Topics

Of the messages about ASBP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	85.71%	16.92%
Technical Analysis	—	—	0%	11.4%
Controversies	—	—	14.29%	0.21%
Analysts	—	—	0%	38.57%
Earnings	—	—	0%	0%
Macro	—	—	0%	32.91%

Announcements· Apr 27

Aspire Biopharma Holdings, Inc. (ASBP) announced a $5 million share buyback program, funded from existing cash.
The company recently raised $21 million in preferred stock offerings in February and April 2026, which was dilutive.
ASBP also announced the acquisition of Dura Control Systems, a global automotive supplier with $200 million in revenue for 2025.

Technical Analysis· Nov 18

$ASBP is showing signs of accumulation, with buyers defending the.10 level three times and every dip since the low being bought instantly.
The stock is displaying textbook strength, with volume exploding on green candles and dying on red, and still holding higher lows and coiling for a potential second leg.
A break over.115 could send the stock back to.12 →.135, with shorts potentially getting caught off guard.

Generated by AI

Community

Of the messages about ASBP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	33.33%	31.82%	28.27%
Newcomers	0%	66.67%	68.18%	71.73%

Regulars· Sep 9

The Aspire-Lakewood Holdings Board has approved a $10M share repurchase program, effective immediately, which is backed by the company's 2025 revenue of ~$209.5M and Adjusted EBITDA of $22.3M.
The company's financial performance has improved, with DCSC H1 2026 revenue of ~$103.9M and Adjusted EBITDA of $10.5M, indicating a growth trend.
The company's previous CEO's legal problems led to a contingent purchase-price obligation, which was satisfied through future sales of the product, and the intellectual property was successfully transferred to Aspire-Lakewood.

Newcomers· Aug 11

Aspire Biopharma's stock price has surged by 77.62% to $7.79, with strong breakout and pumping volume observed.
The company has announced a $30M deal to acquire DCS, expanding its business into the global automotive industry and diversifying its revenue streams into new markets.
Aspire Biopharma's stock has broken out and is pumping higher, with clear breakout signals and explosive surge observed, indicating a strong momentum in the market.

Generated by AI

Aspire Biopharma Holdings

Social

Sep 9

Bullish· Jun 12

Bearish· Jun 12

Announcements· Apr 27

Technical Analysis· Nov 18

Regulars· Sep 9

Newcomers· Aug 11

Aspire-Lakewood Holdings changes auditor, appoints CBIZ CPAs as new firm

Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program

Aspire Biopharma changes name to Aspire-Lakewood Holdings

Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal

Also Discussed

Aspire Biopharma Holdings, Inc.

Company Information

Location

Aspire-Lakewood Holdings changes auditor, appoints CBIZ CPAs as new firm

Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program

Aspire Biopharma changes name to Aspire-Lakewood Holdings

Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal

Also Discussed

Social

Sep 9

Bullish· Jun 12

Bearish· Jun 12

Announcements· Apr 27

Technical Analysis· Nov 18

Regulars· Sep 9

Newcomers· Aug 11